SCHEMBL6858155

SCHEMBL6858155

CCCCOc1c(I)cc(Oc2c(I)cc(CC(=O)O)cc2I)cc1I

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 11/20 0.70
▸ THRA P10827 9/20 0.70
▸ PPARG P37231 4/20 0.70
▸ RXRA P19793 3/20 0.70
▸ ITGB3 P05106 3/20 0.70
▸ ITGAV P06756 3/20 0.70
▸ PCNA P12004 6/20 0.61
▸ LMNA P02545 4/20 0.61
▸ ADORA3 P0DMS8 3/20 0.61
▸ PDE4D Q08499 3/20 0.61
▸ HSD17B10 Q99714 3/20 0.61
▸ CYP1A2 P05177 2/20 0.61
▸ PGR P06401 2/20 0.61
▸ HTR1A P08908 2/20 0.61
▸ CYP2C9 P11712 2/20 0.61
▸ HTR2B P41595 2/20 0.61
▸ POLB P06746 2/20 0.61
▸ HIF1A Q16665 2/20 0.61
▸ ABCB11 O95342 1/20 0.61
▸ CHRM2 P08172 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23709875 0.90 THRB (0.61) THRBTHRAPPARGRXRAITGB3
SCHEMBL25955807 0.88 THRB (0.68) THRBTHRAPPARGRXRAITGB3
SCHEMBL12764500 0.88 THRB (0.68) THRBTHRAPPARGRXRAITGB3
SCHEMBL12764501 0.88 THRB (0.68) THRBTHRAPPARGRXRAITGB3
SCHEMBL19696744 0.87 THRB (0.76) THRBTHRAPPARGRXRAITGB3
SCHEMBL14239798 0.86 THRB (0.66) THRBTHRAPPARGRXRAITGB3
SCHEMBL1814819 0.86 THRB (0.66) THRBTHRAPPARGRXRAITGB3
SCHEMBL25819213 0.86 THRB (0.70) THRBTHRAPPARGRXRAITGB3
SCHEMBL25819214 0.86 THRB (0.70) THRBTHRAPPARGRXRAITGB3
SCHEMBL23709876 0.86 THRB (0.62) THRBTHRAPPARGRXRAITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105482-A1 COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS VASCULAR VISION PHARMACEUTICAL COMPANY (US) 2011-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105482-A1 COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS TEK, THRA, TSHR THRB 4/4885THRA 2/4885PPARG 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback